defibrotide sold brand name defitelio mixture singlestranded oligonucleotides purified intestinal mucosa pigs used treat venoocclusive disease liver people bone marrow transplant different limitations us european union works protecting cells lining blood vessels liver preventing blood clotting way well common side effects include abnormally low blood pressure hypotension diarrhea vomiting nausea nosebleeds epistaxis serious potential side effects identified include bleeding hemorrhage allergic reactions defibrotide used people bleeding complications taking blood thinners medicines reduce bodys ability form use drug generally limited strong risk lifethreatening bleeding brain eyes lungs gastrointestinal tract urinary tract nose people hypersensitivity defibrotide approved medical use european union october united states march australia july defibrotide first fdaapproved therapy treatment severe hepatic vod rare lifethreatening liver european union defibrotide indicated treatment severe hepatic venoocclusive disease vod also known sinusoidal obstructive syndrome sos hematopoietic stemcell transplantation hsct therapy adults adolescents children infants one month defibrotide used treat venoocclusive disease liver people bone marrow transplant different limitations us european however randomized placebo controlled trials hematopoietic stem cell transplantation hsct procedure performed people treat certain blood bone marrow immediately hsct procedure patient receives hepatic vod occur people receive chemotherapy hepatic vod condition veins liver become blocked causing swelling decrease blood flow inside liver may lead liver severe form hepatic vod patient may also develop failure kidneys fewer two percent people develop severe hepatic vod hsct many percent people develop severe hepatic vod administered intravenous infusion doctors office use defibrotide people already taking anticoagulants dangerous use drugs affect platelet aggregation like nsaids done care defibrotide given people difficult time maintaining steady blood high risk bleeding people hypersensitivity reactions common adverse effects occurring people included impaired blood clotting vomiting low blood pressure bleeding brain eyes lungs stomach intestines urine catheterization side effects included diarrhea nosebleeds sepsis graft vs host disease pregnant women take defibrotide women become pregnant taking tested pregnant women normal doses caused hemolytic abortion defibrotides mechanism action poorly understood vitro studies shown protects endothelium lining blood vessels damage fludarabine chemotherapy drug insults like serum starvation also appears increase tpa function decrease plasminogen activator defibrotide mixture singlestranded oligonucleotides chemical name polydeoxyribonucleotide sodium purified intestinal mucosa efficacy defibrotide investigated participants treated three studies two prospective clinical trials expanded access participants enrolled three studies diagnosis hepatic vod liver kidney abnormalities hematopoietic stem cell transplantation studies measured percentage participants still alive days hsct overall three studies percent participants treated defibrotide alive days based published reports analyses participantlevel data expected survival rates days hsct would percent participants severe hepatic vod received supportive care interventions defibrotide approved european union use treating venoocclusive disease liver people bone marrow transplant gentium developed end year jazz pharmaceuticals acquired march us food drug administration fda approved similar defibrotide first fdaapproved therapy treatment severe hepatic vod rare lifethreatening liver fda granted application defibrotide priority review status orphan drug fda granted approval defitelio jazz defibrotide approved medical use japan june defibrotide approved medical use australia july httpsenwikipediaorgwikidefibrotide